Company profile: Great Plains Laboratory
1.1 - Company Overview
Company description
- Provider of research-based clinical laboratory tests for nutritional and metabolic factors in chronic illnesses, including autism, AD(H)D, fibromyalgia, and gastrointestinal and neuropsychiatric disorders. Offers urine- and stool-based profiles like OAT, GI360, MycoTOX, TOXDetect, Glyphosate Test, and IgG Food MAP to assess gut health, toxins, pathogens, and food sensitivities.
Products and services
- GI360 Profile: Comprehensive stool analysis assessing gastrointestinal health by detecting pathogens, viruses, parasites, and bacteria in stool
- MycoTOX Profile: Urine-based test measuring levels of 11 mycotoxins in urine to assess exposure and guide treatment strategies
- Organic Acids Test (OAT): Urine-based test evaluating metabolic pathways to deliver insights into gut health, mitochondrial function, and nutritional status
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Great Plains Laboratory
Biocerna
HQ: United States
Website
- Description: Provider of non-invasive, readily accessible, easy-to-use, and affordable diagnostics, which it develops and commercializes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocerna company profile →
Lantern Pharma
HQ: United States
Website
- Description: Provider of AI, machine learning, and genomics-enabled precision oncology therapies, offering RADR, an AI/ML platform to accelerate cancer drug development, and drug candidates including LP-300 (Phase 2 for relapsed advanced primary lung adenocarcinoma in never smokers), LP-184 (anticancer activity in solid tumors with homologous recombination deficiency), LP-284 (preclinical in non-Hodgkin’s lymphoma and DNA repair-deficient cells), Irofulven, and Dimensa to reduce chemotherapeutic toxicity and treat taxane-induced neuropathies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lantern Pharma company profile →
Siolta Therapeutics
HQ: United States
Website
- Description: Provider of therapeutic microbial consortia and live biotherapeutic products to prevent and treat inflammatory and atopic diseases. Offers the Precision Symbiotics Platform integrating clinical data, bioinformatics, and microbial science; STMC-103H in phase 2 for atopic disease prevention; maternal-infant axis therapeutics; diagnostics for patient stratification; and GMP manufacturing for clinical advancement.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Siolta Therapeutics company profile →
DermTech
HQ: United States
Website
- Description: Provider of non-invasive qPCR assays for skin samples collected via adhesive tape biopsy, analyzing multiple gene targets' RNA expression. Offerings include the DermTech Melanoma Test, a genomic test using adhesive tape-collected skin cells to detect markers associated with melanoma with a 99% negative predictive value, anticipated to be provided through a CLIA-certified laboratory in San Diego.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DermTech company profile →
Celsius Therapeutics
HQ: United States
Website
- Description: Provider of precision medicines for cancer and autoimmune diseases, leveraging single-cell genomics and machine learning to identify therapeutic targets. Offerings include CEL383, an anti-TREM1 antibody in Phase 1 for inflammatory bowel disease, the SCOPE platform for single-cell RNA sequencing–driven analysis, and oncology drug discovery programs based on single-cell tumor analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celsius Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Great Plains Laboratory
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Great Plains Laboratory
2.2 - Growth funds investing in similar companies to Great Plains Laboratory
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Great Plains Laboratory
4.2 - Public trading comparable groups for Great Plains Laboratory
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →